CN111304133A - Culture medium for culturing akkermansia muciniphila and use method and application thereof - Google Patents
Culture medium for culturing akkermansia muciniphila and use method and application thereof Download PDFInfo
- Publication number
- CN111304133A CN111304133A CN202010200526.XA CN202010200526A CN111304133A CN 111304133 A CN111304133 A CN 111304133A CN 202010200526 A CN202010200526 A CN 202010200526A CN 111304133 A CN111304133 A CN 111304133A
- Authority
- CN
- China
- Prior art keywords
- culture medium
- trace elements
- threonine
- glucosamine
- acetyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a culture medium for culturing akkermansia muciniphila, and a use method and application thereof. The culture medium comprises brain heart infusion, porcine gastric mucin, L-cysteine hydrochloride, threonine, N-acetyl-D-glucosamine and vitamins. The culture medium is added with L-cysteine hydrochloride, threonine, N-acetyl-D-glucosamine and vitamins, so that the akkermansia muciniphila can still obtain enough nutrient substances in the culture medium containing the brain heart infusion solution with lower concentration and the pig stomach mucin, and the normal growth and the propagation of the bacterial strain are ensured. After the culture medium provided by the invention is used for culturing the akkermansia muciniphila, the OD value of the obtained bacterial liquid is 0.8211-0.8741.
Description
Technical Field
The invention belongs to the technical field of microbial culture media, and particularly relates to a culture medium for culturing akkermansia muciniphila, and a use method and application thereof.
Background
Ackermanella muciniphila (Akkermansia muciniphila), abbreviated as Akk bacteria, is a gram-negative strictly anaerobic coccus. In 2004, professor delauna and her group isolated Akk bacteria in human intestines, which existed in human digestive tract at about 3-5%, degraded mucin in human intestines, negatively correlated with obesity, diabetes, inflammation and metabolic disorder, and has the effects of delaying aging, inhibiting neurodegenerative diseases, reducing blood lipid and reducing weight.
Low levels of Akk bacteria in the intestine may result in thinning of the mucosal layer, which may lead to a reduced intestinal barrier function, making the intestinal toxins more accessible to the body. Therefore, Akk bacterium is a star bacterium in the recent years of intestinal microbial research. Meanwhile, the Akk bacterium has the functions of improving various diseases of the body, a plurality of scholars regard the Akk bacterium as a probiotic of the next generation, and the preparation taking the Akk bacterium as a main component must have wide development prospect and market.
Akk the optimization of synthetic medium is necessary and crucial for increasing the yield of Akk bacteria. At present, Akk is cultured at home and abroad mostly by a culture medium prepared from bovine brain heart infusion agar dry powder and porcine gastric mucin, and although the culture effect is still good, the cost is high.
CN109810931A discloses a culture medium for culturing Ackermanella muciniphila and a use method thereof, belonging to the technical field of microbial culture media. The components of the culture medium comprise soybean peptone, threonine, glucose, N-acetylglucosamine, sodium chloride and disodium hydrogen phosphate. The culture medium can be used for culturing the bacterial quantity required by the functional research of the akkermansia muciniphila, the component sources of the culture medium are safe, and potential biological hazards do not exist. However, the culture medium can be used for culturing Ackermanella muciniphila without adding bovine brain heart infusion agar dry powder and porcine gastric mucin, and the OD of Akk bacteria is obtained600The value is still low.
Therefore, it is reported whether the addition of other reagents is more beneficial to the culture of Akk bacteria, and the use amount of the bovine brain heart infusion dry powder and the porcine gastric mucin is reduced, so that a better culture effect can be achieved. Therefore, the development of a low-cost culture medium which is beneficial to the growth of the Akk strain is a problem to be solved in the field.
Disclosure of Invention
In view of the problems in the prior art, the invention provides a culture medium for culturing akkermansia muciniphila as well as a using method and application thereof, wherein the culture medium is composed of multiple components, the using amount of bovine brain heart infusion dry powder and porcine gastric mucin is reduced, and the culture medium can achieve a better culture effect by screening other components and scientifically proportioning.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the present invention provides a medium for culturing akkermansia muciniphila, the medium comprising brain heart infusion, porcine gastric mucin, L-cysteine hydrochloride, threonine, N-acetyl-D-glucosamine, and vitamins.
The culture medium comprises L-cysteine hydrochloride, threonine, N-acetyl-D-glucosamine and vitamins in addition to brain heart infusion and porcine gastric mucin. Cysteine is a reducing agent, can consume oxygen in a culture medium, and is beneficial to anaerobic growth of akkermansia muciniphila. Threonine, N-acetyl-D-glucosamine and vitamins can also improve the content of carbon and nitrogen in the culture medium, the N-acetyl-D-glucosamine is a basic composition unit of a plurality of important polysaccharides in organisms and can provide a carbon source, and the vitamins are used as growth factors and can promote the growth of bacteria and are all nutrient substances required for maintaining the normal growth and reproduction of the strains.
As a preferable technical scheme of the invention, the culture medium comprises 25-40g/L of brain heart infusion, 1.5-6g/L of porcine gastric mucin, 0.1-5g/L L-cysteine hydrochloride, 1-10g/L of threonine, 1-10g/L N-acetyl-D-glucosamine and vitamin with the mass fraction of 0.01-0.05%, wherein the mass fraction represents the ratio of the vitamin to the total mass of the culture medium.
When the concentration of each component in the culture medium is in the range, the Akk bacteria are preferably cultured, if the concentration is lower than the minimum concentration, the nutrition of the culture medium is possibly insufficient, and if the concentration is higher than the maximum concentration, the growth and the reproduction of the Akk bacteria are not coordinated, so that the growth condition is not good. In order to ensure that the strain can normally grow and develop, the culture medium must have enough carbon and nitrogen nutrients, and the proportion of carbon and nitrogen should be paid attention to, so that the requirements of the vegetative growth stage on the nutrients can be ensured, and the reproductive growth can be smoothly carried out.
In the present invention, the concentration by mass of the brain-heart infusion in the medium is 25 to 40g/L, and may be, for example, 25g/L, 26g/L, 28g/L, 30g/L, 32g/L, 35g/L, 36g/L, 38g/L or 40 g/L.
The mass concentration of the porcine gastric mucin in the culture medium is 0.5-2g/L, and can be, for example, 0.5g/L, 0.6g/L, 0.8g/L, 1g/L, 1.2g/L, 1.4g/L, 1.5g/L, 1.6g/L, 1.8g/L or 2 g/L.
The mass concentration of L-cysteine hydrochloride in the medium is 0.1-5g/L, and may be, for example, 0.1g/L, 0.5g/L, 1g/L, 1.2g/L, 1.5g/L, 1.8g/L, 2g/L, 2.4g/L, 3g/L, 3.5g/L, 4g/L, 5.5g/L, or 5 g/L.
The mass concentration of threonine in the medium is 1-10g/L, and may be, for example, 1g/L, 2g/L, 3g/L, 4g/L, 5g/L, 6g/L, 7g/L, 8g/L, 9g/L, or 10 g/L.
The mass concentration of N-acetyl-D-glucosamine in the culture medium is 1-10g/L, and may be, for example, 1g/L, 2g/L, 3g/L, 4g/L, 5g/L, 6g/L, 7g/L, 8g/L, 9g/L, or 10 g/L.
The mass fraction of the vitamin in the medium may be 0.01 to 0.05%, for example, 0.01%, 0.012%, 0.015%, 0.02%, 0.025%, 0.03%, 0.035%, 0.04%, 0.045%, 0.05%, or the like.
Preferably, the vitamin comprises vitamin K1。
Preferably, the medium is water as a solvent.
As a preferable technical scheme of the invention, the culture medium also comprises trace elements.
Preferably, the trace elements include any one or a combination of two or more of zinc, boron, copper, iron, molybdenum, nickel, manganese or cobalt.
Preferably, the content of the trace element in the medium is 0.05-0.15g/L, and may be, for example, 0.06g/L, 0.07g/L, 0.08g/L, 0.09g/L, 0.1g/L, 0.12g/L, 0.14g/L, or 0.15 g/L.
By adding the trace elements, the viability of the Akk bacteria can be further improved, and the Akk bacteria have more advantages in growth during culture.
As a preferred technical scheme of the invention, the solution containing the trace elements comprises zinc chloride (ZnCl)2) Boric acid (H)3BO3) Copper chloride dihydrate (CuCl)2·2H2O), ferrous chloride tetrahydrate (FeCl)2·4H2O), sodium molybdate dihydrate (Na)2MoO4·2H2O), nickel chloride hexahydrate (NiCl)2·6H2O), manganese chloride tetrahydrate (MnCl)2·4H2O) or cobalt chloride hexahydrate (CoCl)2·6H2O) or a combination of two or more thereof.
Preferably, the formulation of the solution containing the trace element is 0.05-0.1g/L (e.g., 0.05g/L, 0.06g/L, 0.07g/L, 0.08g/L, 0.09g/L, or 0.1g/L, etc.) zinc chloride, 0.05-0.1g/L (e.g., 0.05g/L, 0.06g/L, 0.07g/L, 0.08g/L, 0.09g/L, or 0.1g/L, etc.) boric acid, 0.01-0.02g/L (e.g., 0.01g/L, 0.012g/L, 0.014g/L, 0.016g/L, 0.018g/L, or 0.02g/L, etc.) copper chloride dihydrate, 1-2g/L (e.g/L, 1.2g/L, 1.4g/L, 1.6g/L, 1.02 g/L, 1.8g/L, etc.) chloride tetrahydrate, 0.02-0.03g/L (for example, 0.02g/L, 0.022g/L, 0.024g/L, 0.026g/L, 0.028g/L, or 0.03 g/L) of sodium molybdate dihydrate, 0.02-0.03g/L (for example, 0.02g/L, 0.022g/L, 0.024g/L, 0.026g/L, 0.028g/L, or 0.03 g/L) of nickel chloride hexahydrate, 0.05-0.15g/L (for example, 0.05g/L, 0.07g/L, 0.08g/L, 0.1g/L, 0.12g/L, or 0.15 g/L) of manganese chloride tetrahydrate, and 0.1-0.15g/L of cobalt chloride hexahydrate.
Preferably, the formulation of the solution containing the trace elements is: 0.07g/L of zinc chloride, 0.06g/L of boric acid, 0.015g/L of copper chloride dihydrate, 1.5g/L of ferrous chloride tetrahydrate, 0.025g/L of sodium molybdate dihydrate, 0.025g/L of nickel chloride hexahydrate, 0.1g/L of manganese chloride tetrahydrate and 0.12g/L of cobalt chloride hexahydrate.
In a preferred embodiment of the present invention, the culture medium further comprises a surfactant.
Preferably, the surfactant comprises tween-80. Tween-80 is a good emulsifier and dispersant, and can make nutrient components in the culture medium more uniform.
Preferably, the mass fraction of the surfactant (ratio of surfactant to the total weight of the medium) is 0.01 to 0.02%, and may be, for example, 0.01%, 0.012%, 0.014%, 0.015%, 0.016%, 0.017%, 0.018%, 0.019%, 0.02%, or the like.
As a preferable technical scheme of the invention, the content of each component in the culture medium is as follows:
25-40g/L brain heart infusion, 1.5-5g/L pig gastric mucin, 0.5-2g/L L-cysteine hydrochloride, 3-10g/L threonine, 3-10g/L N-acetyl-D-glucosamine, and vitamin K with mass fraction of 0.01-0.02%10.05-0.15g/L of trace elements and 0.01-0.02% of Tween-80 by mass fraction.
Preferably, the content of each component in the culture medium is as follows: 27-30g/L brain heart infusion, 2-2.5g/L pig gastric mucin, 1.4-1.6g/L L-cysteine hydrochloride, 4-6g/L threonine, and 0.014-0.016% vitamin K14-6g/L N-acetyl-D-glucosamine, 0.08-0.12g/L microelement and 0.014-0.016 percent of Tween-80.
For example, the content of each component in the culture medium can be 29.6g/L brain heart infusion, 1.152g/L pig gastric mucin, 1.5g/L L-cysteine hydrochloride, 5g/L threonine, and 0.015% by weight of vitamin K15g/L N-acetyl-D-glucosamine, 0.1g/L microelement and 0.015 percent of Tween-80 by mass fraction.
In a second aspect, the present invention provides a method of using a culture medium as in the first aspect, the method comprising the steps of:
the bacterial liquid of akkermansia muciniphila is inoculated into the culture medium according to the first aspect for anaerobic culture.
In the invention, the mucinous akkermansia sp feces is obtained by extraction and separation, and the specific steps are as follows:
(1) sample treatment: putting 150mL of physiological saline solution into a 250mL conical flask, sealing, putting the conical flask and the culture medium into an autoclave together, sterilizing at 121 ℃ for 20 minutes, taking out, and cooling. Adding 25g of feces of normal healthy people, shaking, filtering to remove insoluble substances, performing gradient dilution, and selecting 10-3To 10-9And (3) performing seven gradients, centrifuging at 3000r/min, cooling the culture medium to 55 ℃, pouring 15-20mL of the culture medium into the flat plate, then respectively injecting 0.2mL of the culture medium into the flat plate containing the culture medium by using a pipette, uniformly coating, solidifying, and pouring into a closed container containing an anaerobic gas generating bag at 37 ℃ for culturing.
(2) And (3) separation culture: after culturing for 2 weeks at 37 ℃, observing colony morphology, performing gram staining microscopy, selecting a milky colony without impurities around the colony from a solid medium plate, taking 0.2mL of bacterial liquid, coating the bacterial liquid on the plate, and screening until only one bacterium is on the plate, wherein the obtained strain is akkermansia muciniphila.
As a preferable technical scheme of the invention, the concentration of the bacterial liquid is (0.8-1.2) multiplied by 108cfu/mL, for example, may be 0.8X 108cfu/mL、0.85×108cfu/mL、0.9×108cfu/mL、0.95×108cfu/mL、1×108cfu/mL、1.05×108cfu/mL、1.1×108cfu/mL or 1.2X 108cfu/mL, etc.
Preferably, the inoculation amount of the bacterial liquid is 100-200. mu.L, such as 110. mu.L, 120. mu.L, 130. mu.L, 140. mu.L, 150. mu.L, 160. mu.L, 170. mu.L, 180. mu.L, 190. mu.L or 200. mu.L.
Preferably, the temperature of the anaerobic culture is 35-40 ℃, for example, 35 ℃, 36 ℃, 37 ℃, 38 ℃, 39 ℃ or 40 ℃.
Preferably, the anaerobic culture time is 72-96h, such as 72h, 75h, 78h, 80h, 82h, 85h, 88h, 90h, 92h, 94h or 96 h.
As a preferable technical scheme of the invention, the using method comprises the following steps: inoculating the culture medium of the first aspect with a mucophilic eggThe bacterial liquid of the Ackermanella albus, wherein the concentration of the bacterial liquid is (0.8-1.2) multiplied by 108cfu/mL, inoculum size of 100-.
In a third aspect, the invention also provides a use of akkermansia muciniphila cultured by using the culture medium of the first aspect in preparation of a medicament for treating metabolic diseases.
The recitation of numerical ranges herein includes not only the above-recited numerical values, but also any numerical values between any of the above-recited numerical ranges not recited, and for the sake of brevity and clarity, the present invention is not intended to be exhaustive of the specific numerical values encompassed within the range.
Compared with the prior art, the invention has at least the following beneficial effects:
(1) the culture medium provided by the invention comprises brain heart infusion, porcine gastric mucin, L-cysteine hydrochloride and vitamin K1Threonine and N-acetyl-D-glucosamine, wherein the culture medium can provide required nutrient elements for the growth and the propagation of Akk bacteria, and meanwhile, by further adding trace elements and a Tween-80 reagent, more viable bacteria can be obtained than when the culture medium is cultured in a mucin culture medium, which shows that the culture medium provided by the invention can completely realize Akk in-vitro amplification culture.
(2) After Akk bacteria are cultured by the culture medium through a proper culture method, the OD value of the obtained strain is 0.8211-0.8741, and the strain in the culture medium is identified to be Akk bacteria through a PCR technology, so that the culture medium provided by the invention is beneficial to the culture of Akk bacteria, is convenient for preparing Akk bacteria into preparations in the later period, and can realize subsequent functional research and industrial development.
Drawings
FIG. 1 is a DNA sequence comparison of Akk strain cultured in example 1 and Akk strain as standard in the database.
Detailed Description
The technical solutions of the present invention are further described in the following embodiments with reference to the drawings, but the following examples are only simple examples of the present invention and do not represent or limit the scope of the present invention, which is defined by the claims.
In the following examples, the strains and reagents used were purchased from conventional manufacturers and the specific sources are shown in table 1 below:
TABLE 1
| Laboratory strains or reagents | Company(s) |
| Physiological saline | Guangzhou Ruishu biological reagent Co., Ltd |
| Brain heart infusion | Solarbio |
| Porcine gastric mucin | SIGMA |
| Threonine | Shanghai Bioengineering Co., Ltd |
| N-acetyl-D-glucosamine | Shanghai Bioengineering Co., Ltd |
| Ethanol | Shanghai national medicine group |
| Tween-80 | Shanghai Bioengineering Co., Ltd |
| Fast pfu DNA polymerizationEnzyme kit | BEIJING TRANSGEN BIOTECH Co.,Ltd. |
| Primer and method for producing the same | Shanghai Bioengineering Co., Ltd |
| ZnCl2 | Tianjin Chengyuan chemical reagent Co., Ltd |
| H3BO3 | Tianjin Chengyuan chemical reagent Co., Ltd |
| CuCl2·2H2O | Tianjin Chengyuan chemical reagent Co., Ltd |
| FeCl2·4H2O | Tianjin Chengyuan chemical reagent Co., Ltd |
| Na2MoO4·2H2O | Tianjin Chengyuan chemical reagent Co., Ltd |
| NiCl2·6H2O | Shanghai national medicine group |
| MnCl2·4H2O | Tianjin Chengyuan chemical reagent Co., Ltd |
| CoCl2·6H2O | Tianjin Chengyuan chemical reagent Co., Ltd |
In the following examples, the formulation of the trace elements is shown in table 2 below:
TABLE 2
| Chemical composition | Content (g/L) |
| ZnCl2 | 0.07 |
| H3BO3 | 0.06 |
| CuCl2·2H2O | 0.015 |
| FeCl2·4H2O | 1.5 |
| Na2MoO4·2H2O | 0.025 |
| NiCl2·6H2O | 0.025 |
| MnCl2·4H2O | 0.1 |
| CoCl2·6H2O | 0.12 |
In the following examples, the sources of the experimental instruments are shown in table 3 below:
TABLE 3
| Laboratory apparatus | Company(s) |
| Magnetic stirrer | HANGZHOU MIU INSTRUMENTS Co.,Ltd. |
| Electronic balance | SHANGHAI SUNNY HENGPING SCIENTIFIC INSTRUMENT Co.,Ltd. |
| High-speed centrifugal machine | ThermoFisher |
| Vertical high-pressure steam sterilizer | Shanghai Shenan Medical Instrument Factory |
| Enzyme-linked immunosorbent assay (ELISA) instrument | ZHENGZHOU BOSAI BIOENGINEERING Co.,Ltd. |
Example 1
This embodiment provides a culture medium comprising:
7.4g of brain-heart infusion, 0.8g of porcine gastric mucin, 0.3g L-cysteine hydrochloride, 1.0g of threonine and 0.015% of vitamin K11.0g N-acetyl-D-glucosamine, adding water to a constant volume of 200mL, stirringStirring for 30min, transferring into conical flask, and sterilizing.
Example 2
This embodiment provides a culture medium comprising:
7.4g brain heart infusion, 0.8g pig stomach mucin, 0.3g L-cysteine hydrochloride, 1.0g threonine, and 0.015% vitamin K11.0g N-acetyl-D-glucosamine, 0.1mL of trace elements, adding water to a constant volume of 200mL, stirring for 30min, mixing, transferring to a conical flask, and sterilizing.
Example 3
This embodiment provides a culture medium comprising:
7.4g of brain-heart infusion, 0.8g of porcine gastric mucin, 0.3g L-cysteine hydrochloride, 1.0g of threonine and 0.015% of vitamin K11.0g N-acetyl-D-glucosamine, 0.1mL of trace elements and 0.015% of Tween-80 by mass fraction, adding water to a constant volume of 200mL, stirring for 30min, uniformly mixing, transferring into a conical flask, and sterilizing.
Example 4
This example provides a medium which differs from example 3 only in that the amount of porcine gastric mucin is 0.48 g.
Example 5
This example provides a medium which differs from example 3 only in that the amount of porcine gastric mucin is 0.4 g.
Example 6
This embodiment provides a culture medium comprising:
7.4g brain heart infusion, 0.4g pig stomach mucin, 0.45g L-cysteine hydrochloride, 1.5g threonine, and 0.02 wt% vitamin K11.5g N-acetyl-D-glucosamine, 0.15mL of trace elements and 0.02% of Tween-80 by mass fraction, adding water to a constant volume of 200mL, stirring for 30min, uniformly mixing, transferring into a conical flask, and sterilizing.
Example 7
This example provides a medium which differs from example 3 in that: the weight of the brain-heart infusion is 5.92g, and the weight of the pig stomach mucin is 0.48 g.
Example 8
This example provides a medium which differs from example 3 in that: the weight of the brain-heart infusion is 5.5g, and the weight of the pig stomach mucin is 0.48 g.
Example 9
The difference from example 3 is that the mass of L-cysteine hydrochloride in the medium is 1 g.
Example 10
The difference from example 3 is that the mass of L-cysteine hydrochloride in the medium is 0.1 g.
Example 11
The difference from example 3 is that the mass of threonine in the medium is 2 g.
Example 12
The difference from example 3 is that the mass of threonine in the medium is 0.5 g.
Example 13
The difference from example 3 is that the medium vitamin K1Is 0.05% by mass.
Example 14
The difference from example 3 is that the mass of N-acetyl-D-glucosamine in the medium is 2 g.
Comparative example 1
This comparative example provides a culture medium comprising:
adding water into 7.4g brain-heart infusion and 0.8g pig stomach mucin, diluting to constant volume of 200mL, stirring for 30min, transferring into conical flask, and sterilizing.
Comparative example 2
This comparative example provides a culture medium comprising:
adding water to a constant volume of 200mL for 7.4g of brain-heart infusion, 0.8g of pig gastric mucin and 0.3g L-cysteine hydrochloride, stirring for 30min, transferring into a conical flask, and sterilizing.
Comparative example 3
This comparative example provides a culture medium comprising:
adding water to a volume of 200mL for 7.4g of brain-heart infusion, 0.8g of pig gastric mucin, 0.3g L-cysteine hydrochloride and 1.0g of threonine, stirring for 30min, transferring into a conical flask, and sterilizing.
Comparative example 4
This comparative example provides a culture medium comprising:
7.4g brain-heart infusion, 0.8g pig stomach mucin, 0.3g L-cysteine hydrochloride, 1.0g threonine, 0.2mL vitamin K1Adding water to a constant volume of 200mL, stirring for 30min, mixing, transferring into a conical flask, and sterilizing.
Comparative example 5
The difference from example 3 is that L-cysteine hydrochloride was replaced by lysine hydrochloride in the medium.
Comparative example 6
The difference from example 3 is that N-acetyl-D-glucosamine is replaced by glucose in the medium.
Comparative example 7
The difference from example 3 is that the medium was supplemented with a single iron element instead of trace elements.
Performance testing
Ackermanella muciniphila was cultured using the media provided in examples 1 to 16 and comparative examples 1 to 7.
Detection of OD value
Sterilizing the culture medium at high temperature, cooling, inoculating Ackermansia muciniphila (1 × 10)8cfu/mL, 200. mu.L), inoculating, placing in a closed container, placing two anaerobic gas generating bags at the same time, culturing at 37 ℃, taking out after 4 days, centrifuging at 3000rpm for 10min, then resuspending the precipitate with 2mL sterile PBS, adding into a 96-well plate, 200. mu.L per well, and using PBS as blank control.
The OD value of the bacterial liquid was measured at 630nm using a microplate reader, and the measurement was repeated three times, and the average value was taken, and the results are shown in Table 4.
TABLE 4
As shown in the table, the Akk strain culture medium provided by the invention can ensure that the strains can normally grow, and the OD values of the Akk strain culture medium are all larger than 0.82; and as can be seen from examples 3, 4 and 5, when the content of the porcine gastric mucin was changed alone, the culture effect was best when the mass of the porcine gastric mucin was 0.48 g; from examples 4, 7 and 8, it is understood that the culture effect is best when the brain-heart infusion content is changed alone, and the brain-heart infusion content is 5.92.
As can be seen from the above table, the optimal solution of the culture medium prepared in the present invention is: 5.92g brain heart infusion, 0.48g pig stomach mucin, 0.3g L-cysteine hydrochloride, 1.0g threonine, 0.2mL vitamin K11.0g N-acetyl-D-glucosamine, 0.1mL of trace elements and 0.1mL of Tween-80, and adding water to a constant volume of 200 mL.
2. Purification of mucins
The mucin has more impurities, the impure culture medium is turbid and opaque, the impurities can be removed after purification, and the culture medium is transparent and not turbid.
Dissolving mucin in water, and stirring at 30-35 deg.C for 5 hr to obtain mixed solution; centrifuging the mixed solution at 3000rpm for 10min, collecting supernatant, adding ethanol, standing for 4h, removing supernatant to obtain precipitate, dissolving with water, repeatedly washing with ethanol for 2 times, and dissolving the precipitate with water to obtain purified mucin.
3. Identification of the type of Strain in the Medium
Extracting the cultured AKK bacteria DNA, detecting the DNA concentration by using nanodrop 2000, taking 5 mu L of DNA, and amplifying the AKK bacteria DNA sequence by using the following primers:
upstream primer (SEQ ID NO. 1): CAAGTCGAACGAGAGAATTGCTAGC the flow of the air in the air conditioner,
downstream primer (SEQ ID NO. 2): CATCCCAGTTACCAGTCTCACCTT are provided.
The PCR reaction system is shown in Table 5 below:
TABLE 5
| Reagent | Content (μ L) |
| Fast |
1 |
| 5X Fast pfu buffer | 10 |
| dNTP(2.5mM) | 2 |
| AKK upstream primer (10. mu.M) | 2 |
| AKK downstream primer (10. mu.M) | 2 |
| AKK bacteria DNA (34 ng/. mu.L) | 5 |
| 3dH2O | 28 |
| Total volume | 50 |
The PCR reaction conditions are shown in Table 6 below:
TABLE 6
Adding 5 mu L of total PCR products into 1 mu L of DNA loading buffer, performing electrophoresis by using 1% agarose gel, collecting pictures by using a Chemi Doc XRS + imager, sending the rest PCR products to Shanghai biological engineering Limited company for sequencing by using an upstream primer, wherein the obtained sequence is SEQ ID NO.3, comparing the obtained result by using a BLAST program of NCBI, and the result of comparing the sequencing result with data of Akk bacteria in the NCBI is shown in figure 1, wherein the data similarity is 100%, and the cultured strains are all Akk bacteria.
In conclusion, the culture medium provided by the invention can provide required nutrient elements for the growth and propagation of Akk bacteria, can obtain more viable bacteria than the viable bacteria obtained by culturing in a mucin culture medium, completely realizes the in vitro expansion culture of Akk bacteria, and has the advantages of good culture effect and low culture cost.
The applicant declares that the present invention illustrates the detailed structural features of the present invention through the above embodiments, but the present invention is not limited to the above detailed structural features, that is, it does not mean that the present invention must be implemented depending on the above detailed structural features. It should be understood by those skilled in the art that any modifications of the present invention, equivalent substitutions of selected components of the present invention, additions of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
SEQUENCE LISTING
<110> Suzhou Prisisen Gene science and technology, Inc
<120> culture medium for culturing akkermansia muciniphila, and use method and application thereof
<130>20200313
<160>3
<170>PatentIn version 3.3
<210>1
<211>25
<212>DNA
<213> Artificial Synthesis
<400>1
caagtcgaac gagagaattg ctagc 25
<210>2
<211>24
<212>DNA
<213> Artificial Synthesis
<400>2
catcccagtt accagtctca cctt 24
<210>3
<211>480
<212>DNA
<213>Akkermansia muciniphila
<400>3
gggtgagtaa cacgtgagta acctgccccc cagagcggga tagccctggg aaactgggat 60
taataccgca tagtatcgaa agattaaagc agcaatgcgc ttggggatgg gctcgcggcc 120
tattagttag ttggtgaggt aacggctcac caaggcgatg acgggtagcc ggtctgagag 180
gatgtccggc cacactggaa ctgagacacg gtccagacac ctacgggtgg cagcagtcga 240
gaatcattca caatggggga aaccctgatg gtgcgacgcc gcgtggggga atgaaggtct 300
tcggattgta aacccctgtc atgtgggagc aaattaaaaa gatagtacca caagaggaac 360
agacggctaa ctctgtgcca gcagccgcgg taatacagag gtctcaagcg ttgttcggaa 420
tcactgggcg taaagcgtgc gtaggctgtt tcgtaagtcg tgtgtgaaag gcgcgggctc 480
Claims (10)
1. A culture medium for culturing Ackermanella muciniphila, said culture medium comprising brain heart infusion, porcine gastric mucin, L-cysteine hydrochloride, threonine, N-acetyl-D-glucosamine, and vitamins.
2. The culture medium according to claim 1, wherein the culture medium comprises a concentration of 25-40g/L brain-heart infusion, 1.5-6g/L porcine gastric mucin, 0.1-5g/L L-cysteine hydrochloride, 1-10g/L threonine, 1-10g/L N-acetyl-D-glucosamine, and a mass fraction of 0.01-0.05% of vitamins;
preferably, the vitamin comprises vitamin K1；
Preferably, the medium is water as a solvent.
3. The culture medium according to claim 1 or 2, further comprising trace elements;
preferably, the trace elements comprise any one or a combination of more than two of zinc, boron, copper, iron, molybdenum, nickel, manganese or cobalt;
preferably, the content of the trace elements in the culture medium is 0.05-0.15 g/L.
4. The culture medium according to any one of claims 1 to 3, wherein the solution containing the trace elements comprises any one or a combination of two or more of zinc chloride, boric acid, copper chloride dihydrate, ferrous chloride tetrahydrate, sodium molybdate dihydrate, nickel chloride hexahydrate, manganese chloride tetrahydrate, or cobalt chloride hexahydrate;
preferably, the formulation of the solution containing the trace elements is:
0.05-0.1g/L of zinc chloride, 0.05-0.1g/L of boric acid, 0.01-0.02g/L of copper chloride dihydrate, 1-2g/L of ferrous chloride tetrahydrate, 0.02-0.03g/L of sodium molybdate dihydrate, 0.02-0.03g/L of nickel chloride hexahydrate, 0.05-0.15g/L of manganese chloride tetrahydrate and 0.1-0.15g/L of cobalt chloride hexahydrate.
5. The culture medium according to any one of claims 1 to 4, further comprising a surfactant;
preferably, the surfactant comprises tween-80;
preferably, the mass fraction of the surfactant is 0.01 to 0.02%.
6. A culture medium according to any one of claims 1 to 5, comprising the following components:
25-40g/L brain heart infusion, 1.5-5g/L pig gastric mucin, 0.5-2g/L L-cysteine hydrochloride, 3-10g/L threonine, 3-10g/L N-acetyl-D-glucosamine, and vitamin K with mass fraction of 0.01-0.02%10.05-0.15g/L of trace elements and 0.01-0.02% of Tween-80 by mass fraction;
further preferably, the culture medium comprises the following components:
27-30g/L brain-heart infusion, 2-2.5g/L pig gastric mucin, 1.4-1.6g/L L-cysteine hydrochloride, 4-6g/L threonine, 4-6g/L N-acetyl-D-glucosamine, and vitamin K with mass fraction of 0.014-0.016%10.08-0.12g/L of trace elements and 0.014-0.016% of Tween-80.
7. A method of using the culture medium according to any one of claims 1 to 6, comprising the steps of:
the culture medium according to any one of claims 1 to 6 is inoculated with a bacterial solution of Ackermanella muciniphila, and anaerobic culture is carried out.
8. The use method according to claim 7, wherein the concentration of the bacterial liquid is (0.8-1.2) × 108cfu/mL；
Preferably, the inoculation amount of the bacterial liquid is 100-;
preferably, the temperature of the anaerobic culture is 35-40 ℃;
preferably, the anaerobic culture time is 72-96 h.
9. Use according to claim 7 or 8, characterized in that it comprises the following steps:
inoculating the culture medium according to any one of claims 1 to 7 with a bacterial solution of Ackermanella muciniphila, the concentration of the bacterial solution being (0.8 to 1.2). times.108cfu/mL, inoculum size of 100-.
10. Use of akkermansia muciniphila cultured with the medium according to claims 1 to 6 for the manufacture of a medicament for the treatment of metabolic diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010200526.XA CN111304133B (en) | 2020-03-20 | 2020-03-20 | Culture medium for culturing akkermansia muciniphila and use method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010200526.XA CN111304133B (en) | 2020-03-20 | 2020-03-20 | Culture medium for culturing akkermansia muciniphila and use method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111304133A true CN111304133A (en) | 2020-06-19 |
| CN111304133B CN111304133B (en) | 2023-01-13 |
Family
ID=71151448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010200526.XA Active CN111304133B (en) | 2020-03-20 | 2020-03-20 | Culture medium for culturing akkermansia muciniphila and use method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111304133B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113265359A (en) * | 2021-05-26 | 2021-08-17 | 广西壮族自治区兽医研究所 | Improved liquid culture method of akkermansia muciniphila |
| CN114350571A (en) * | 2022-02-09 | 2022-04-15 | 广州知易生物科技有限公司 | Non-animal-derived culture medium and method for culturing akkermansia muciniphila by using same |
| CN114410473A (en) * | 2022-02-09 | 2022-04-29 | 广州知易生物科技有限公司 | Method for separating Ackermanella from breast milk and product |
| CN114540246A (en) * | 2022-03-17 | 2022-05-27 | 中国科学院亚热带农业生态研究所 | Selective medium of AKK (alkyl ketene dimer) bacteria and separation and identification method |
| CN115287233A (en) * | 2022-08-10 | 2022-11-04 | 暨南大学附属第一医院（广州华侨医院） | Ackermanella composite culture medium, and powder prepared from same and application of Ackermanella composite culture medium |
| CN115975885A (en) * | 2022-12-23 | 2023-04-18 | 中国农业大学 | Preparation of akkermansia muciniphila culture medium by using fish processing byproducts as nitrogen source |
| WO2023116227A1 (en) * | 2021-12-22 | 2023-06-29 | 苏州普瑞森生物科技有限公司 | Microbial combination having weight loss effect and application thereof |
| CN118028187A (en) * | 2024-04-12 | 2024-05-14 | 微康益生菌(苏州)股份有限公司 | Culture medium for separating and purifying mucin-philin Acremonium and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017178496A1 (en) * | 2016-04-11 | 2017-10-19 | Wageningen Universiteit | Novel bacterial species |
| CN107384828A (en) * | 2017-08-22 | 2017-11-24 | 中国农业科学院农产品加工研究所 | Acker Man slime bacteria culture medium and preparation method thereof |
| CN107849093A (en) * | 2015-05-06 | 2018-03-27 | 瓦赫宁恩大学 | The method for cultivating Ackermam Salmonella |
| CN109810931A (en) * | 2019-04-03 | 2019-05-28 | 广州康泽医疗科技有限公司 | A kind of culture medium and its application method for cultivating thermophilic mucin Ackermam Salmonella |
| CN110079474A (en) * | 2019-04-12 | 2019-08-02 | 沈阳药科大学 | A kind of method of the thermophilic mucin bacterium of High Density Cultivation Ai Keman |
-
2020
- 2020-03-20 CN CN202010200526.XA patent/CN111304133B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107849093A (en) * | 2015-05-06 | 2018-03-27 | 瓦赫宁恩大学 | The method for cultivating Ackermam Salmonella |
| WO2017178496A1 (en) * | 2016-04-11 | 2017-10-19 | Wageningen Universiteit | Novel bacterial species |
| CN109415683A (en) * | 2016-04-11 | 2019-03-01 | 瓦赫宁恩大学 | Novel bacteria species |
| CN107384828A (en) * | 2017-08-22 | 2017-11-24 | 中国农业科学院农产品加工研究所 | Acker Man slime bacteria culture medium and preparation method thereof |
| CN109810931A (en) * | 2019-04-03 | 2019-05-28 | 广州康泽医疗科技有限公司 | A kind of culture medium and its application method for cultivating thermophilic mucin Ackermam Salmonella |
| CN110079474A (en) * | 2019-04-12 | 2019-08-02 | 沈阳药科大学 | A kind of method of the thermophilic mucin bacterium of High Density Cultivation Ai Keman |
Non-Patent Citations (1)
| Title |
|---|
| 艾纯明等: "《表面活性剂在溶浸采矿中的应用》", 31 July 2019, 中国矿业大学出版社 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113265359A (en) * | 2021-05-26 | 2021-08-17 | 广西壮族自治区兽医研究所 | Improved liquid culture method of akkermansia muciniphila |
| WO2023116227A1 (en) * | 2021-12-22 | 2023-06-29 | 苏州普瑞森生物科技有限公司 | Microbial combination having weight loss effect and application thereof |
| CN114350571A (en) * | 2022-02-09 | 2022-04-15 | 广州知易生物科技有限公司 | Non-animal-derived culture medium and method for culturing akkermansia muciniphila by using same |
| CN114410473A (en) * | 2022-02-09 | 2022-04-29 | 广州知易生物科技有限公司 | Method for separating Ackermanella from breast milk and product |
| CN114410473B (en) * | 2022-02-09 | 2024-01-30 | 广州知易生物科技有限公司 | Method for separating Acremonium from breast milk and product |
| CN114350571B (en) * | 2022-02-09 | 2024-04-19 | 广州知易生物科技有限公司 | Non-animal-derived culture medium and method for culturing Acremonium muciniphilum by using same |
| CN114540246A (en) * | 2022-03-17 | 2022-05-27 | 中国科学院亚热带农业生态研究所 | Selective medium of AKK (alkyl ketene dimer) bacteria and separation and identification method |
| CN115287233A (en) * | 2022-08-10 | 2022-11-04 | 暨南大学附属第一医院（广州华侨医院） | Ackermanella composite culture medium, and powder prepared from same and application of Ackermanella composite culture medium |
| CN115975885A (en) * | 2022-12-23 | 2023-04-18 | 中国农业大学 | Preparation of akkermansia muciniphila culture medium by using fish processing byproducts as nitrogen source |
| CN118028187A (en) * | 2024-04-12 | 2024-05-14 | 微康益生菌(苏州)股份有限公司 | Culture medium for separating and purifying mucin-philin Acremonium and application thereof |
| CN118028187B (en) * | 2024-04-12 | 2024-07-02 | 微康益生菌(苏州)股份有限公司 | Culture medium for separating and purifying mucin-philin Acremonium and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111304133B (en) | 2023-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111304133B (en) | Culture medium for culturing akkermansia muciniphila and use method and application thereof | |
| JP7240751B2 (en) | Feed products based on novel microbial biomass | |
| CN109810931A (en) | A kind of culture medium and its application method for cultivating thermophilic mucin Ackermam Salmonella | |
| CN115851500B (en) | Lactobacillus plantarum and application thereof | |
| CN109355349B (en) | Ackermansoni specificity screening culture medium and preparation method and application thereof | |
| CN114350571B (en) | Non-animal-derived culture medium and method for culturing Acremonium muciniphilum by using same | |
| CN115141775B (en) | Culture method for improving self efficacy and selenium-enriched capability of probiotics and application of culture method | |
| CN110982868A (en) | Co-culture method for improving triterpene content of ganoderma lucidum and application | |
| Ullah et al. | Isolation of selenium‐resistant bacteria and advancement under enrichment conditions for selected probiotic Bacillus subtilis (BSN313) | |
| CN118389306A (en) | Saccharomyces cerevisiae B2904 and application thereof in reducing trans-fatty acid content | |
| CN1880471A (en) | Method for detecting bifidobacteria in milk product | |
| CN116355784B (en) | Microbacterium strain for producing siderophores and application thereof | |
| CN115029273B (en) | Lactobacillus fermentum TY-G03 and application thereof | |
| CN113481120B (en) | Culture medium, preparation method thereof and method for culturing bacteroides fragilis by using culture medium | |
| CN113397170B (en) | Application of marine prebiotics composition for regulating human intestinal flora | |
| CN111560451B (en) | Economical and efficient method for batch determination of intestinal tract thalli external growth and interaction rule | |
| CN115161254A (en) | Method for improving yield of extracellular vesicles of lactic acid bacteria | |
| CN110760467B (en) | Lactobacillus fermentum and application thereof in functional yellow wine | |
| CN113930367A (en) | Lactic acid bacteria with cholesterol-reducing performance and application thereof | |
| CN101173249A (en) | Method for inducing human fetal liver mesenchyma stem cell to pancreatic islet beta sample cell differentiation | |
| CN111004734A (en) | Lactobacillus rhamnosus capable of regulating and controlling relative abundance of acinetobacter in intestinal tract | |
| CN115820463B (en) | Preparation method of siderophores based on microbial fermentation | |
| CN118325998B (en) | Soybean peptide for enhancing immunity and reducing three highs and preparation method thereof | |
| Irzoqy et al. | Inhibitory Effect of Saccharomyces cerevisiae Against Propionibacterium acnes | |
| CN117487664B (en) | Bifidobacterium separation culture method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 215123 unit 505, A5 / F, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou City, Jiangsu Province Applicant after: Suzhou preyson Biotechnology Co.,Ltd. Address before: 215123 unit 505, A5 / F, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou City, Jiangsu Province Applicant before: SUZHOU PRECISION GENE Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |